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ABSTRACT 
Background. Neutrophils play a role in the pathogenesis of asthma, chronic obstructive 
pulmonary disease and pulmonary infection. Impaired neutrophil phagocytosis predicts 
hospital-acquired infection. Despite this, remarkably few neutrophil-specific treatments exist.  
Objectives. To identify novel pathways for the restoration of effective neutrophil 
phagocytosis, and to activate such pathways effectively in neutrophils from patients with 
impaired neutrophil phagocytosis. 
Methods. Blood neutrophils were isolated from healthy volunteers and from patients with 
impaired neutrophil function. In healthy neutrophils, phagocytic impairment was induced 
experimentally using beta-2 agonists. Inhibitors and activators of cyclic AMP (cAMP)-
dependent pathways were used to assess the influence on neutrophil phagocytosis in vitro. 
Results. Beta-2 agonists and corticosteroids inhibited neutrophil phagocytosis. Impairment of 
neutrophil phagocytosis by beta-2 agonists was associated with significantly reduced RhoA 
activity. Inhibition of protein kinase A (PKA) restored phagocytosis and RhoA activity, 
suggesting that cAMP signals through PKA to drive phagocytic impairment. Cyclic AMP can 
however signal through effectors other than PKA, such as exchange protein directly activated 
by cAMP (EPAC). An EPAC-activating analog of cAMP (8CPT-2Me-cAMP) reversed 
neutrophil dysfunction induced by beta-2 agonists or corticosteroids, but did not increase 
RhoA activity. 8CPT-2Me-cAMP reversed phagocytic impairment induced by Rho kinase 
inhibition, but was ineffective in the presence of Rap1 GTPase inhibitors. 8CPT-2Me-cAMP 
restored function to neutrophils from patients with known, acquired impairment of neutrophil 
phagocytosis.  
Conclusions. EPAC activation consistently reverses clinical and experimental impairment of 
neutrophil phagocytosis. EPAC signals through Rap1and bypasses RhoA. EPAC activation 
represents a novel potential means by which to reverse impaired neutrophil phagocytosis. 
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CLINICAL IMPLICATIONS 
EPAC activation and/or Rap-1 specific signaling represent potential ‘drugable’ targets for the 
restoration of functioning neutrophil phagocytosis, at a time when neutrophil-specific 
therapies are distinctly lacking in clinical practice. 
 
 
CAPSULE SUMMARY 
EPAC reverses impaired neutrophil phagocytosis via Rap-1. As neutrophil dysfunction in 
critical illness predicts infection, and as this restorative mechanism in neutrophils is 
previously unreported, EPAC homologs could theoretically prevent infection without 
recourse to antibiotics. 
 
 
KEY WORDS 
Neutrophil; beta-2 agonist; cyclic AMP; exchange protein directly activated by cAMP 
(EPAC); hospital-acquired infection. 
 
ABBREVIATIONS 
AKAP   A kinase anchoring protein 
APACHE  Acute physiology and chronic health evaluation 
6-Bnz-cAMP  N6-benzoyladenosine-cAMP 
cAMP   Cyclic adenosine monophosphate 
COPD   Chronic obstructive pulmonary disease 
ELISA   Enzyme-linked immunosorbent assay 
EPAC   Exchange protein directly activated by cAMP 
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GM-CSF  Granulocyte macrophage colony-stimulating factor 
HAI   Hospital-acquired infection 
IMDM   Iscove’s modified Dulbecco’s medium 
MOI   Multiplicity of infection 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
P. aeruginosa  Pseudomonas aeruginosa 
PBS   Phosphate-buffered saline 
PGE1   Prostaglandin E1 
PKA   Protein kinase A 
SAPS   Simplified acute physiology score 
S. aureus  Staphylococcus aureus 
SOFA   Sequential organ failure assessment   
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INTRODUCTION 
 
Neutrophils are central to the pathogenesis of a wide variety of common and important 
clinical conditions including chronic obstructive pulmonary disease (COPD) and asthma 
(particularly corticosteroid-resistant asthma).1-3 Patients with COPD and asthma are 
commonly prescribed long-term inhaled beta-2 agonists and corticosteroids. The detailed 
effects of these treatments on neutrophil phagocytic function are relatively poorly understood, 
though it has been suggested that beta-2 agonists can impair neutrophil function.4 
 
It is also increasingly recognized that acquired neutrophil dysfunction is common in critically 
ill patients,5 and is independently associated with a significantly increased risk of subsequent 
hospital-acquired infection (HAI).6 Impaired neutrophil function can be restored to normal, ex 
vivo, through administration of granulocyte-macrophage colony-stimulating factor (GM-
CSF).6 This suggests the potential to develop pharmacological strategies to restore specific 
defects in neutrophil function for clinical benefit. The potential importance of developing 
non-antibiotic-based pharmacological prevention strategies is enormous. For example, at a 
conservative estimate there are 1.7 million HAIs in the US annually,7 at a time when 
antibiotic resistance is a global concern and few new antibiotics are in development.  
The aims of this study were therefore to characterize the effects of beta-2 agonists, 
corticosteroids and critical illness on neutrophil function, and to identify novel ways of 
modulating pathways involved in the impairment of neutrophil phagocytosis, in the hope of 
identifying candidates with the potential to restore efficient phagocytosis.  
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METHODS 
 
Reagents 
Salbutamol, salmeterol, isoprenaline, fluticasone, beclomethasone, budesonide, SQ 22536, 
ICI 118,551, atenolol, prostaglandin E1 (PGE1), Y27632, zymosan derived from 
Saccharomyces cerevisiae and Giemsa staining solution were from Sigma Aldrich 
(Gillingham, UK). KT5720, mouse anti-human GM-CSF receptor antibody (IgG2a), and 
murine IgG2a negative control antibody were from Merck (Darmstadt, Germany). St-Ht31 
and St-Ht31 control peptide were from Promega (Madison, USA). Antibodies against RhoA 
and protein kinase A (PKA) were from Cell Signaling (Hitchin, UK). Dextran was from 
Pharmacosmos (Holbaek, Denmark).  Percoll Plus was from GE Healthcare (Little Chalfont, 
UK). Iscove’s Modified Dulbecco’s Medium (IMDM) was from Life Technologies (Paisley, 
UK). 8CPT-2Me-cAMP, N6-benzoyladenosine-cAMP (6-Bnz-cAMP) and GGTi 298 were 
from Tocris Bioscience (Bristol, UK). PKA inhibitor IV was from Santa Cruz Biotechnology 
(Dallas, TX, USA), ESI-09 was from Biolog (Bremen, Germany). Rho G-lisa was from 
Cytoskeleton (Denver, USA). PKA activity assay was from Abcam (Cambridge, UK). 
 
Ethical approvals 
Ethical approval to obtain neutrophils from healthy volunteers was granted by the County 
Durham and Tees Valley Research Ethics Committee. Approval to obtain neutrophils from 
patients was granted by the Yorkshire and the Humber - Leeds West Research Ethics 
Committee. Ethical approval relating to the BALTI-2 trial was granted by the Oxford A 
Research Ethics Committee. 
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Isolation of peripheral blood neutrophils 
Neutrophils were isolated from whole blood by dextran sedimentation and fractionation over   
discontinuous Percoll gradients as previously described.8 Only samples yielding ≥ 95% 
neutrophil purity (assessed by morphological analysis) and ≥ 95% viability (assessed by 
trypan blue exclusion) were used.  
 
Phagocytosis assay 
Phagocytosis of serum-opsonized zymosan by neutrophils was assessed as previously 
described.5 A variety of reagents were incorporated into the phagocytosis assay, individually 
or in combination, to determine the effect on phagocytosis. Doses for each condition are 
described in figure legends or in the Results section. All incubations described were 
performed at 37°C in 5% CO2. Unless otherwise stated, neutrophils were prepared in IMDM 
containing 1% autologous serum, and were adherent to tissue culture plastic. In all 
experiments in which salbutamol, salmeterol, corticosteroids or PGE1 were used to impair 
neutrophil phagocytosis, the application was for 30 minutes, prior to the addition of serum-
opsonized zymosan for a further 30 minutes. Phagocytosis was quantified in terms of the 
proportion of neutrophils containing 2 or more zymosan particles at light microscopy. 
 
Bacterial Killing Assay 
The ability of neutrophils to kill live bacteria was assessed using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay as previously 
described.9 Briefly, bacteria (laboratory strains of Staphylococcus aureus NCTC 8325 or 
Pseudomonas aeruginosa PA01, and clinical strains of S. aureus (methicillin sensitive – 
strain 97 STA) and P. aeruginosa (42 PSA) isolated from patients with ventilator-associated 
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pneumonia were added to 5x105 neutrophils at a multiplicity of infection (MOI) of 10 and 
incubated at 37°C/5% CO2 for 30 minutes. Cells were then lysed with Triton X-100 before 
the addition of 20µl of MTT (5mg/ml). MTT metabolized to yield a purple color by live 
bacteria was solubilized in isopropanol and the OD560 measured. The percentage bacteria 
killed was determined by comparing values to a standard curve prepared by diluting the initial 
bacterial dose to represent 0, 30, 60 and 90% of bacteria killed versus the OD560 value. 
 
RhoA and PKA activity assays 
RhoA and PKA activity were measured using an enzyme-linked immunosorbent assay 
(ELISA; Rho G-lisa) as per the manufacturer’s instructions. Neutrophils were adhered to 
tissue culture plates before being exposed to serum-opsonized zymosan or vehicle control for 
5 minutes. Cells were washed in ice-cold phosphate-buffered saline (PBS) and then lysed. 
Aliquots were taken for estimation of total protein with the remainder snap frozen in liquid 
nitrogen and stored at -80°C. Samples were equalized for total protein concentration and 
analyzed using a BMG FluoStar Optima plate reader. Samples were assessed for total RhoA 
and total PKA by boiling in Laemmli sample buffer before Western blot analysis using anti-
RhoA or anti-PKA antibodies. 
 
Statistical Analysis 
The Statistical Package for the Social Sciences17.0 (IBM, USA) was used.  In the figures 
shown, unless otherwise stated, results are derived from 6 independent experiments (ie 
conditions performed using neutrophils from 6 different donors). Statistical comparisons were 
by one-way ANOVA with Bonferroni’s post-hoc correction, and data expressed as mean (bar) 
and standard error of the mean (error bars). P values <0.05 were considered statistically 
significant, and in the figures * = p<0.05, ** = p<0.01, *** = p<0.001. 
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RESULTS 
 
With the exception of results shown in Figure 7 C and D, all data relate to neutrophils derived 
from healthy volunteers.  
 
Incubation of neutrophils from healthy volunteers with the short-acting beta-2 agonist 
salbutamol resulted in a dose-dependent impairment of phagocytosis (Figure 1A). The long-
acting beta-2 agonist salmeterol induced a similar effect (Figure 1A). Neither salbutamol nor 
salmeterol influenced neutrophil viability at the concentrations used (data not shown). The 
selective beta-2 antagonist ICI 118,551 prevented the anti-phagocytic effects of salbutamol 
and salmeterol, without inhibiting the impairment of phagocytosis induced by the beta-1 
agonist isoprenaline. In contrast, atenolol (a predominantly beta-1 antagonist with partial 
beta-2 antagonist activity) prevented the anti-phagocytic effect of isoprenaline, but not the 
effects of salbutamol or salmeterol (Figure 1B). The inhibitory effects of salbutamol on 
neutrophil phagocytosis were also reduced, in a dose-dependent manner, by the adenylate 
cyclase inhibitor SQ22536, (Figure 1C). Salbutamol at 10µM was used to induce reproducible 
phagocytic impairment in later experiments, unless otherwise stated. 
 
Incubation of neutrophils with the glucocorticoids beclomethasone, fluticasone and 
budesonide resulted in a dose-dependent impairment of neutrophil phagocytosis (Figure 2A). 
The combination of beclomethasone and salbutamol produced an effect similar to salbutamol 
alone (Figure 2B). 
 
The results in Figure 1 suggested that beta-2 agonist-induced impairment of neutrophil 
phagocytosis is mediated via cyclic adenosine monophosphate (cAMP), and that mechanisms 
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downstream of cAMP signaling may provide novel opportunities for pharmacologic 
restoration of neutrophil phagocytosis. PGE1 was selected as a separate stimulus known to 
increase intracellular cAMP. PGE1 was incubated with neutrophils, and produced a similar 
impairment of phagocytosis (Figure 3A). PKA is a key target for intracellular cAMP, and is 
located at strategic compartmentalized locations within cells through interaction with A 
kinase anchoring proteins (AKAPs).10  Pre-incubation of neutrophils with St-Ht31 (a cell-
permeable inhibitor of AKAPs) prevented impairment of neutrophil phagocytosis mediated 
by salbutamol (Figure 3B).  This suggested that cAMP impairs neutrophil phagocytosis 
predominantly via activation of PKA. To test this further, salbutamol-treated neutrophils were 
pre-incubated with two separate PKA inhibitors, KT5720 and PKA inhibitor IV. Both 
inhibitors prevented salbutamol-induced impairment of phagocytosis. (Figure 3C). We further 
demonstrated that a PKA-specific cAMP analogue, 6-Bnz-cAMP, significantly reduced 
neutrophil phagocytosis (Figure 3D).  
 
In parallel with the studies of phagocytosis described, we confirmed that salbutamol increases 
PKA activity in neutrophils and that this effect can be blocked by a PKA inhibitor (Figure 
4A). RhoA is inherently involved in cytoskeletal organization in the neutrophil,11 and 
adequate function of RhoA is pivotal to effective phagocytosis. To investigate the 
downstream mechanisms of salbutamol-induced impairment of phagocytosis further, we 
therefore studied the effect of salbutamol on RhoA activity. Salbutamol significantly reduced 
RhoA activity in neutrophils exposed to zymosan, without affecting the total amount of RhoA 
proteins (Figure 4B). This effect could be significantly abrogated by PKA inhibition (Figure 
4B). These findings suggested that salbutamol stimulates PKA, which inhibits RhoA activity, 
which in turn impairs phagocytosis of zymosan.  
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The data presented in Figures 3 and 4, in addition to our previous data,6 suggested that RhoA 
plays a part in regulating efficient phagocytosis. The next question was whether phagocytosis 
could be restored through other intracellular pathways, when RhoA activity was blocked. The 
role of PKA both in mediating beta-2-induced impairment of phagocytosis and in reducing 
RhoA activity was interesting in this regard, as cAMP can exert divergent functions in cells, 
depending on whether it engages PKA or alternative effectors. One such alternative effector is 
EPAC (exchange protein directly activated by cAMP), which is typically associated with 
Rap-1 signaling.12-14 We therefore used an analog of cAMP that selectively activates EPAC 
(8CPT-2Me-cAMP) to determine the effect of routing cAMP away from the RhoA pathway. 
8CPT-2Me-cAMP reversed salbutamol-induced impairment of phagocytosis (Figure 5A, 
“salbutamol” columns). The protective effect was removed by an EPAC-specific inhibitor, 
ESI-09 (Figure 5A, “salbutamol” columns). GM-CSF, which can reverse impaired neutrophil 
phagocyosis induced by C5a or by critical illness,6 also reversed salbutamol-mediated 
phagocytic impairment (Figure 5A, “salbutamol” columns). However ESI-09 could not 
prevent the protective effect of GM-CSF, implying that GM-CSF does not act through EPAC 
(Figure 5A, “salbutamol” columns). All of these results could be replicated when PGE1was 
substituted for salbutamol (Figure 5A, “PGE1” columns).  
 
To test the role of RhoA in restoration of phagocytosis by GM-CSF and 8CPT-2Me-cAMP, 
the Rho kinase inhibitor Y27632 was also used to drive impairment of neutrophil 
phagocytosis. Under these circumstances 8CPT-2Me-cAMP, but not GM-CSF, was capable 
of restoring neutrophil phagocytosis (Figure 5A, “Y27632” columns). This indicated that 
GM-CSF exerts its restorative effect through RhoA, while 8CPT-2Me-cAMP does not. 
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We therefore went on to study the effects of EPAC activation on RhoA activity. Interestingly, 
application of 8CPT-2Me-cAMP to healthy neutrophils reduced RhoA activity by 63% 
(Figure 5B, left panel). Furthermore, 8CPT-2Me-cAMP had no effect on salbutamol-induced 
impairment of Rho activity (Figure 5B, right panel). Both these results contrasted with the 
effects of GM-CSF (Figure 5B), which were more like those for PKA inhibition (Figure 4B). 
This suggested that 8CPT-2Me-cAMP does not exert its protective effects on phagocytosis 
through RhoA. As EPACs can act as guanine-exchange proteins for the Rap family,13 we 
tested whether a Rap inhibitor (GGTi 298) could interfere with the protective effects of 
8CPT-2Me-cAMP. GGTi 298 significantly abrogated the protective effects of 8CPT-2Me-
cAMP on phagocytosis (Figure 5C). To confirm that 8CPT-2Me-cAMP exerted none of its 
effects through the GM-CSF receptor, we incubated neutrophils with an antibody that blocks 
the GM-CSF receptor. The blocking antibody prevented the phagocytosis-protective effects of 
GM-CSF, but not those of 8CPT-2Me-cAMP (Figure 5D). The effect of glucocorticoids on 
phagocytosis could also be partly restored by 8CPT-2Me-cAMP (Figure 5E).  
 
Figure 5 indicates an effect of 8CPT-2Me-cAMP on phagocytosis of inert particles. In order 
to test a more relevant physiological response, the effect on bacterial killing was assessed. 
8CPT-2Me-cAMP significantly restored the capacity of neutrophils to kill laboratory and 
clinical strains of the Gram positive pathogen S. aureus (Figure 6A and B) and the Gram 
negative pathogen P. aeruginosa (Figure 6C and D).  
 
Collectively, the results above suggested that neutrophil phagocytosis can be impaired 
through a PKA-dependent pathway. They further suggested that selective EPAC activation 
can bypass this pathway, thereby representing a potentially novel means to restore neutrophil 
phagocytosis. They also suggested that the protective effects exerted by 8CPT-2Me-cAMP 
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and GM-CSF are independent of one another. We therefore sought to test the potential 
clinical relevance of these findings in two scenarios.  
 
Firstly, plasma from patients in the BALTI-2 trial (a randomized controlled trial of 
intravenous salbutamol versus placebo in critically ill patients),15 was applied to healthy 
neutrophils. On six separate occasions plasma from patients (n=13 who received placebo, n=5 
who received salbutamol) was applied in a blinded fashion to neutrophils isolated from 
healthy volunteers (ie six separate healthy volunteers provided neutrophils, the plasma applied 
was the same each time). Plasma from salbutamol-treated and placebo-treated patients 
impaired neutrophil phagocytosis to a similar degree (Figure 7A). Given the striking degree 
of phagocytic impairment induced by plasma from critically ill patients, these experiments 
were repeated to determine whether 8CPT-Me-cAMP could reverse this effect. Both 8CPT-
2Me-cAMP and GM-CSF reversed the anti-phagocytic effect of the plasma (Figure 7B).  
 
Secondly, neutrophils were isolated from the blood of 16 critically ill patients at high risk of 
nosocomial infection (8 male, 8 female; median age 66 (range 25-82) years). All patients 
were: admitted to ICU within the last 48 hours; met criteria for the systemic inflammatory 
response syndrome (SIRS); and required the support of at least one organ system. Clinical 
parameters included mean Acute Physiology and Chronic Health Evaluation (APACHE) II 
score of 23.1 (standard deviation (SD) 8.4), Simplified Acute Physiology Score II (SAPS II) 
of 42.3 (SD 10.0) Sequential Organ Failure Assessment (SOFA) score of 9.0 (SD 4.1, n=15 
due to missing data in 1 patient), and PaO2:FiO2 ratio 173 mmHg (SD 78, n=15 due to 
missing data in 1 patient). The principal diagnoses were pneumonia (n=7), urinary sepsis 
(n=3), infective endocarditis, biliary sepsis, pancreatitis, multiple trauma, acute colitis, and 
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post-operative peritonitis (all n=1). Both treatments resulted in significant improvement in 
phagocytic capacity (Figures 7C and 7D). 
 
A schematic summary of our main findings is shown in Figure 8.  
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DISCUSSION 
 
The findings presented here may have potential clinical implications for critically ill patients 
at the highest risk of developing hospital-acquired infection,6 where EPAC activation and/or 
selective signaling through Rap-1 emerge as interesting areas for possible therapeutic 
exploration. The capacity to restore efficient killing of Gram positive and Gram negative 
pathogens commonly implicated in HAI is encouraging in this regard. While EPAC activators 
have not been used clinically to date, they have shown promise in, for example, in vivo 
models of macular degeneration.16  
 
Our overall findings extend data showing that the generation of cAMP impairs neutrophil 
phagocytosis. In our hands, the beta-2 agonist effect could be abolished by selective inhibitors 
of PKA, suggesting that cAMP selectively targets PKA in neutrophils. In several cell types, 
cAMP is directed to PKA through the activity of AKAPs.17,18 This process appears to be 
replicated in neutrophils, which are known to contain AKAPs,19 and in our experiments an 
AKAP inhibitor was also capable of partially restoring phagocytosis in beta-2 agonist-treated 
neutrophils.  
 
The anti-phagocytic activity of beta-2 agonists appeared to be mediated, at least in part, by 
inhibition of RhoA. Similar findings have been described for impaired phagocytosis induced 
by excessive C5a.5 This suggests a similar downstream mechanism for impairment of 
neutrophil phagocytosis mediated through the beta-2 receptor, PGE1 receptor, and CD88 (the 
receptor for C5a). The implication is that RhoA inhibition is a central downstream process in 
mediating the phagocytic impairment induced by engaging these receptors. A similarly 
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important role for RhoA in regulating complement-mediated phagocytosis has been described 
in murine macrophages.20  
 
A key finding of our study was that, in striking contrast to GM-CSF, EPAC activation not 
only failed to restore salbutamol-driven impairment of RhoA activation, but knocked down 
constitutive RhoA. Despite this, both GM-CSF and the EPAC activator could completely 
reverse beta-2 agonist- and PGE1-induced impairment of neutrophil phagocytosis. This 
formed the basis for the observation that EPAC and GM-CSF have alternative modes of 
action. In keeping with this, Rho kinase inhibition prevented phagocytic restoration caused by 
GM-CSF, but had no effect on the restorative effects of EPAC activation (Figure 5A). Taken 
together these findings suggested that GM-CSF and EPAC activation, while both capable of 
restoring phagocytosis, had opposing effects on RhoA. EPAC is known to signal through 
Rap-1 in other cell types,21,22 raising the possibility that EPAC may selectively signal through 
Rap-1, bypassing RhoA. The confirmation of two independent pathways for restoration of 
neutrophil phagocytosis is novel, to our knowledge, though interestingly a similar situation 
has been described in a murine macrophage cell line.23 
 
Certain cautions are required when considering our data. For example, our ex vivo conditions 
may be insufficiently representative of those in situ. Our experiments were performed in 
blood neutrophils adhered to tissue culture plastic, and it is unlikely that phagocytic capacity 
(and response to molecules such as EPAC analogues or GM-CSF) would be replicated 
identically in neutrophils within body tissues. Any implications around the significance of our 
findings in tissue neutrophils therefore remain necessarily speculative. In addition, our 
routinely used concentration of salbutamol,10 µM, is higher than that often described in 
clinical scenarios. The original BALTI trial generated estimated salbutamol concentrations in 
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the low micromolar range.24 Our rationale for studying plasma from patients in the BALTI-2 
trial related to the use of intravenous beta-2 agonists. In hindsight, while salbutamol 
concentrations were not specifically measured in the BALTI-2 study, we were always 
unlikely to observe any effect of salbutamol over and above the profound anti-phagocytic 
effect of plasma from critically ill patients.  
 
In addition, we focused on neutrophil phagocytosis. The concentrations of salbutamol used 
have been shown to reduce neutrophil chemotaxis in other studies.25 We concentrated on 
phagocytosis because impaired ex vivo phagocytosis of serum-opsonized zymosan predicts 
nosocomial infection in a clinical setting.6 We should emphasize that in our bacterial killing 
experiments (Figure 6) in particular we cannot infer that the effectiveness of GM-CSF or 8-
CPT-2Me-cAMP is attributable to effects on phagocytosis alone, as effects on many other 
innate immune functions of neutrophils could be contributing.  
 
Furthermore, interpretation of studies of this nature may be constrained by lack of absolute 
specificity of inhibitors. For example molecules such as KT5720 can influence targets other 
than PKA, and Y27632 certainly does not inhibit all RhoA functions. Finally, in advocating 
the further study of EPAC analogs or Rap-1 activators as potential therapeutics, we must 
obviously remain alert to the fact that EPAC and Rap-1 are involved in multiple homeostatic 
processes, and future work will be required to take due consideration of potential toxicities.  
 
In summary, EPAC activation represents a novel potential therapeutic avenue for the 
restoration of neutrophil phagocytosis, and deserves further investigation.     
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FIGURE LEGENDS 
 
Figure 1: β adrenergic receptor agonists inhibit human neutrophil phagocytosis in 
an adenylate cyclase-dependent manner.  
 (A) Neutrophils were pre-incubated with the short-acting beta-2 agonist salbutamol or 
the long-acting beta-2 agonist salmeterol and phagocytosis of zymosan quantified. 
Statistical comparisons are with bar of the same color in the left-hand column. (B) In a 
variation, neutrophils were first treated with atenolol (100 µM) or the selective beta-2 
antagonist ICI 118,551 (10 µM) for 30 minutes before exposure to either salbutamol (10 
µM), salmeterol (10 µM) or the beta-1 agonist isoprenaline (10 µM). Statistical 
comparisons are between the bars indicated. (C) In a separate variation, neutrophils were 
pre-incubated with the adenylate cyclase inhibitor SQ 22536 before incubation with 
salbutamol (10 µM). Statistical comparisons are with the left-hand column..  
 
Figure 2: Glucocorticoids inhibit neutrophil phagocytosis in a dose-dependent 
manner. 
 (A) Neutrophils were pre-incubated with fluticasone, beclomethasone and budesonide, 
and phagocytosis of zymosan quantified. Statistical comparisons are with the bar of the 
same color in the left hand panel. (B) Neutrophils were pre-incubated with salbutamol 
(10µM), beclomethasone (10µM) or a combination of the two, and phagocytosis 
quantified. Statistical comparison is with the left hand column. 
 
Figure 3: Inhibition of neutrophil phagocytosis by β2 agonists is PKA-dependent.  
(A) Neutrophils were pre-incubated with salbutamol or prostaglandin E1 or a 
combination, and phagocytosis of zymosan quantified. Statistical comparisons are with 
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the left hand column. (B) Neutrophils were pre-incubated with the AKAP inhibitory 
peptide St-Ht31, control or peptide control prior to addition of vehicle control or 
salbutamol (10µM), and phagocytosis quantified. Statistical comparisons are as 
indicated by horizontal bars. (C) Neutrophils were pre-incubated with the PKA 
inhibitors KT5720 (final concentration 5 µM) or PKA inhibitor IV (1 µM) for 30 
minutes prior to  addition of salbutamol (10µM) or prostaglandin E1 (1µM), then 
phagocytosis was quantified. Statistical comparisons are as indicated by horizontal bars. 
(D) Neutrophils were pre-incubated with vehicle control, St-Ht31 (20µM) or the peptide 
control for St-Ht31 (20µM) prior to the addition of vehicle control or the PKA-selective 
cAMP analogue 6-Bnz-cAMP (10µM), and phagocytosis of zymosan quantified. 
Statistical comparisons are with the nearest black bar to the left. 
 
Figure 4: Inhibition of neutrophil phagocytosis by β2 agonists is associated with 
down-regulation of RhoA.   
(A) Neutrophils were pre-incubated with the PKA inhibitor KT5720 (5 µM) for 30 minutes, 
before addition of salbutamol or control. Zymosan (grey and white bars) or no zymosan 
(black bars) was then added for 5 minutes, and the reaction stopped. PKA activity was 
estimated by ELISA (upper panel) and total PKA protein and β-actin were assessed by 
Western blot (lower panel). (B) In a variation of (A), RhoA activity and protein were assessed 
instead of PKA. For both (A) and (B) statistical comparisons are with the nearest white 
column. Data are representative of 5 independent experiments. 
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Figure 5: β2 agonist-induced dysfunction of neutrophil phagocytosis is rescued by 
an EPAC activator which acts independently of the GM-CSF receptor.  
(A) Neutrophils were pre-incubated with salbutamol, prostaglandin E1 (1 µM) or the Rho 
kinase inhibitor Y27632 (10 µM) +/- the EPAC inhibitor ESI-09 (10 µM) for 30 minutes, 
prior to the addition of the EPAC activator 8CPT-2Me-cAMP (final concentration 50 µM) or 
GM-CSF (0.3nM) for 30 minutes. Phagocytosis was quantified. Statistical comparisons are 
with the nearest black bar to the left. (B) Neutrophils were pre-incubated with salbutamol 
before incubation with human recombinant GM-CSF (0.3 nM), or 8CPT-2Me-cAMP (50µM). 
Serum-opsonized zymosan was then added for 5 minutes. Cells were then placed on ice and 
lysed. RhoA activity was estimated by ELISA.Statistical comparisons are with the nearest 
black bar to the left. (C) Neutrophils were pre-incubated with the Rap-1 inhibitor GGTi 298 
(10 µM) or medium alone for 30 minutes before incubation with salbutamol with or without 
human recombinant GM-CSF (0.3nM) or 8CPT-2Me-cAMP (50µM) for 30 minutes. 
Phagocytosis was quantified. Statistical comparisons are indicated by the horizontal bars. (D) 
Neutrophils were pre-incubated with GM-CSF receptor blocking antibody (100 ng/ml) or 
negative control antibody (100ng/ml) for 30 minutes before exposure to salbutamol with or 
without GM-CSF (0.3nM) or 8CPT-2Me-cAMP (50µM) for 30 minutes. Phagocytosis was 
quantified.. Statistical comparisons are indicated by the horizontal bars. (E) Neutrophils were 
pre-incubated with salbutamol, beclomethasone (10µM) or a combination before exposure to 
vehicle control, GM-CSF (0.3nM) or 8CPT-2Me-cAMP (50µM) for 30 minutes. 
Phagocytosis was quantified. Statistical comparisons are with the nearest black bar to the left. 
 
Figure 6: β2 agonist-induced impairment of bacterial killing is prevented by EPAC 
activation. 
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Neutrophils were pre-incubated with salbutamol before incubation with human recombinant 
GM-CSF (0.3 nM), or 8CPT-2Me-cAMP (50µM). A S. aureus lab strain (Panel A), 
methicillin-sensitive S. aureus clinical strain (Panel B), P. aeruginosa lab strain (Panel C) or 
P. aeruginosa clinical strain (Panel D) were added (MOI 10) and incubated at 37°C/5% CO2 
for 30 minutes. Cells were lysed with Triton X-100 before the addition of 20µl of MTT 
(5mg/ml), the OD560 was measured, and the percentage bacterial killing estimated from 
standard curves. Results are expressed as the percentage of starting bacteria killed. Values are 
mean +/- SEM from 7 and 8 independent experiments for S. aureus and P. aeruginosa 
respectively. Statistical comparisons are with the second (salb) column in each panel. 
 
Figure 7: EPAC activation restores phagocytic function both to neutrophils exposed to 
anti-phagocytic plasma and to dysfunctional neutrophils from critically ill patients at 
high risk of nosocomial infection. 
(A) Neutrophils were pre-incubated with plasma (1:10 dilution) from 18 patients involved in 
either limb of the BALTI-2 trial (5 had received intravenous salbutamol, 13 had received 
intravenous placebo), or with medium alone (control) for 30 minutes. Salbutamol added to 
neutrophils (second column) acted as a positive control. Zymosan (opsonized using serum 
from the healthy volunteer who provided the neutrophils on any given day) was added and 
phagocytosis quantified. Values are mean +/- SEM from six independent experiments [ie, on 
a given day, prior to addition of oponized zymosan, one healthy donor’s neutrophils were 
exposed to medium (“control” column), salbutamol (“salbutamol” column), plasma from each 
of 5 salbutamol-treated patients, with the mean rate of phagocytosis calculated (“salbutamol 
patients” column), or plasma from each of 13 placebo-treated patients, with the mean rate of 
phagocytosis calculated (“placebo patients” column); this experiment was repeated using 
neutrophils from 6 different healthy donors, using mean values from the 6 experiments]. (B) 
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Neutrophils were pre-incubated with plasma (1:10 dilution) from 6 patients involved in either 
limb of the BALTI-2 trial (3 had received intravenous salbutamol, 3 had received intravenous 
placebo), or with medium alone (control) for 30 minutes.  Cells were then treated with human 
recombinant GM-CSF (0.3 nM) or 8CPT-2Me-cAMP (50 µM) or medium alone for 30 
minutes.  Zymosan (opsonized using serum from the healthy volunteer who provided the 
neutrophils on any given day) was then added for 30 minutes, and phagocytosis quantified. (C 
and D) Neutrophils were isolated from the blood of 16 critically ill patients and adhered to 
tissue culture plastic before incubation with either (C) human recombinant GM-CSF (0.3 nM) 
or (D) 8CPT-2Me-cAMP (50 µM) for 30 minutes prior to the addition of autologous serum-
opsonized zymosan for a further 30 minutes. Phagocytosis was quantified. Data are shown as 
lines connecting individual data points from each individual patient, with or without the 
relevant treatment. The heavy horizontal line indicates the median value. Data were analyzed 
using the Wilcoxon rank sum test. 
 
Figure 8: Schematic representation of main findings.  
The picture represents a neutrophil, divided into 3 illustrative sections. Section 1 is a 
schematic of normal phagocytosis. Upon engagement of the appropriate phagocytic receptor, 
opsonized zymosan is thought to signal through RhoA, which plays a part in coordinating 
polymerization of filamentous actin (F-actin), allowing the efficient organization of the 
phagosome, with subsequent phagocytosis. Section 2 illustrates the proposed disruption of 
this system by beta-2 agonists or PGE1. These stimuli generate cAMP, which appears to 
preferentially activate PKA, through interaction with AKAP. Activation of PKA inhibits 
RhoA activation, preventing efficient phagocytosis. Other anti-phagocytic stimuli, such as an 
excess of C5a, also appear to exert their effects through inhibition of RhoA.6 Section 3 
demonstrates the proposed restorative role for EPAC activation. We propose that cAMP 
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preferentially activates PKA in neutrophils in response to stimuli that impair phagocytosis. 
Directing cAMP through EPAC results in signaling through Rap-1, which allows efficient 
phagocytosis to proceed, even when RhoA is simultaneously blocked. On the left of the 
diagram, GM-CSF is seen engaging with its receptor on the neutrophil. GM-CSF can 
replenish RhoA activity, but if Rho kinase is blocked the effects of GM-CSF are abrogated. In 
contrast, even when Rho kinase is blocked, EPAC activation can still rescue phagocytosis, 
suggesting that EPAC activation and GM-CSF restore phagocytosis through independent 
mechanisms. 
 
